These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
183 related articles for article (PubMed ID: 26130461)
1. Evaluation of Epigenetic Drug Targeting of Heterogenous Tumor Cell Fractions Using Potential Biomarkers of Response in Ovarian Cancer. Singh AK; Chandra N; Bapat SA Clin Cancer Res; 2015 Nov; 21(22):5151-63. PubMed ID: 26130461 [TBL] [Abstract][Full Text] [Related]
2. Genome-wide methylation profiling of ovarian cancer patient-derived xenografts treated with the demethylating agent decitabine identifies novel epigenetically regulated genes and pathways. Tomar T; de Jong S; Alkema NG; Hoekman RL; Meersma GJ; Klip HG; van der Zee AG; Wisman GB Genome Med; 2016 Oct; 8(1):107. PubMed ID: 27765068 [TBL] [Abstract][Full Text] [Related]
3. Epigenetic regulation of IQGAP2 promotes ovarian cancer progression via activating Wnt/β-catenin signaling. Deng Z; Wang L; Hou H; Zhou J; Li X Int J Oncol; 2016 Jan; 48(1):153-60. PubMed ID: 26549344 [TBL] [Abstract][Full Text] [Related]
4. Pharmacologic inhibition of epigenetic modifications, coupled with gene expression profiling, reveals novel targets of aberrant DNA methylation and histone deacetylation in lung cancer. Zhong S; Fields CR; Su N; Pan YX; Robertson KD Oncogene; 2007 Apr; 26(18):2621-34. PubMed ID: 17043644 [TBL] [Abstract][Full Text] [Related]
5. Integrative prediction of gene function and platinum-free survival from genomic and epigenetic features in ovarian cancer. Wrzeszczynski KO; Varadan V; Kamalakaran S; Levine DA; Dimitrova N; Lucito R Methods Mol Biol; 2013; 1049():35-51. PubMed ID: 23913207 [TBL] [Abstract][Full Text] [Related]
6. Genome-wide transcriptional response to 5-aza-2'-deoxycytidine and trichostatin a in multiple myeloma cells. Heller G; Schmidt WM; Ziegler B; Holzer S; Müllauer L; Bilban M; Zielinski CC; Drach J; Zöchbauer-Müller S Cancer Res; 2008 Jan; 68(1):44-54. PubMed ID: 18172295 [TBL] [Abstract][Full Text] [Related]
7. Pharmacologic inhibition of epigenetic modification reveals targets of aberrant promoter methylation in Ewing sarcoma. Nestheide S; Bridge JA; Barnes M; Frayer R; Sumegi J Pediatr Blood Cancer; 2013 Sep; 60(9):1437-46. PubMed ID: 23508900 [TBL] [Abstract][Full Text] [Related]
9. The potential of DNA modifications as biomarkers and therapeutic targets in oncology. Jankowska AM; Millward CL; Caldwell CW Expert Rev Mol Diagn; 2015; 15(10):1325-37. PubMed ID: 26394702 [TBL] [Abstract][Full Text] [Related]
10. Epigenetic and genetic alterations of p33ING1b in ovarian cancer. Shen DH; Chan KY; Khoo US; Ngan HY; Xue WC; Chiu PM; Ip P; Cheung AN Carcinogenesis; 2005 Apr; 26(4):855-63. PubMed ID: 15677627 [TBL] [Abstract][Full Text] [Related]
11. Transcriptional silencing of the TMS1/ASC tumour suppressor gene by an epigenetic mechanism in hepatocellular carcinoma cells. Zhang C; Li H; Zhou G; Zhang Q; Zhang T; Li J; Zhang J; Hou J; Liew CT; Yin D J Pathol; 2007 Jun; 212(2):134-42. PubMed ID: 17471463 [TBL] [Abstract][Full Text] [Related]
12. Integrative genome-wide expression and promoter DNA methylation profiling identifies a potential novel panel of ovarian cancer epigenetic biomarkers. Gloss BS; Patterson KI; Barton CA; Gonzalez M; Scurry JP; Hacker NF; Sutherland RL; O'Brien PM; Clark SJ Cancer Lett; 2012 May; 318(1):76-85. PubMed ID: 22155104 [TBL] [Abstract][Full Text] [Related]
13. Genome-wide analysis of epigenetic silencing identifies BEX1 and BEX2 as candidate tumor suppressor genes in malignant glioma. Foltz G; Ryu GY; Yoon JG; Nelson T; Fahey J; Frakes A; Lee H; Field L; Zander K; Sibenaller Z; Ryken TC; Vibhakar R; Hood L; Madan A Cancer Res; 2006 Jul; 66(13):6665-74. PubMed ID: 16818640 [TBL] [Abstract][Full Text] [Related]
14. Epigenetic inactivation of the tumor suppressor gene RIZ1 in hepatocellular carcinoma involves both DNA methylation and histone modifications. Zhang C; Li H; Wang Y; Liu W; Zhang Q; Zhang T; Zhang X; Han B; Zhou G J Hepatol; 2010 Nov; 53(5):889-95. PubMed ID: 20675009 [TBL] [Abstract][Full Text] [Related]
15. TGF-β induces global changes in DNA methylation during the epithelial-to-mesenchymal transition in ovarian cancer cells. Cardenas H; Vieth E; Lee J; Segar M; Liu Y; Nephew KP; Matei D Epigenetics; 2014 Nov; 9(11):1461-72. PubMed ID: 25470663 [TBL] [Abstract][Full Text] [Related]
16. Epigenetic Therapies in Ovarian Cancer Alter Repetitive Element Expression in a McDonald JI; Diab N; Arthofer E; Hadley M; Kanholm T; Rentia U; Gomez S; Yu A; Grundy EE; Cox O; Topper MJ; Xing X; Strissel PL; Strick R; Wang T; Baylin SB; Chiappinelli KB Cancer Res; 2021 Oct; 81(20):5176-5189. PubMed ID: 34433584 [TBL] [Abstract][Full Text] [Related]
17. Incubation with somatostatin, 5-aza decitabine and trichostatin up-regulates somatostatin receptor expression in prostate cancer cells. Liu Z; Marquez M; Nilsson S; Holmberg AR Oncol Rep; 2008 Jul; 20(1):151-4. PubMed ID: 18575731 [TBL] [Abstract][Full Text] [Related]
18. Epigenetic biomarkers in epithelial ovarian cancer. Gloss BS; Samimi G Cancer Lett; 2014 Jan; 342(2):257-63. PubMed ID: 22245949 [TBL] [Abstract][Full Text] [Related]
19. Gene silencing of MIR22 in acute lymphoblastic leukaemia involves histone modifications independent of promoter DNA methylation. Li X; Liu J; Zhou R; Huang S; Huang S; Chen XM Br J Haematol; 2010 Jan; 148(1):69-79. PubMed ID: 19807731 [TBL] [Abstract][Full Text] [Related]